The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

SUMMIT, N.J., Dec. 9, 2019 /PRNewswire/ -- Seqirus announced today results from a prospective, cluster-randomized trial led by a team of researchers from Brown University that showed FLUAD(®), an ...

Meeting Coverage > IDWeek Fluad on Par With High-Dose Flu Vax in High-Risk Seniors — Real-world data also shows higher effectiveness with adjuvanted trivalent flu vaccine vs standard ...

Trivalent Fluad, meanwhile, scored accelerated approval in 2015, also on the condition that Seqirus demonstrate the vaccine’s efficacy in a post-approval trial.

“There are two currently marketed vaccines specifically indicated for the patient segment aged 65 years and older, the Seqirus’ adjuvanted vaccine Fluad trivalent and Sanofi’s Fluzone High ...

New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza ...

SAN FRANCISCO, Oct. 3, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, will present new healthcare and cost outcomes data for its MF59®-adjuvanted trivalent influenza ...

Fluad (Seqirus), the first adjuvanted influenza vaccine specifically developed for those aged ≥65, is now available for the 2016/17 flu season.

The Medicines and Healthcare products Regulatory Agency has cleared the adjuvanted trivalent influenza vaccine Fluad for use in people aged 65 years or older.

Active seniors star in the new Seqirus commercial for Fluad, its first for the trivalent flu vaccine aimed at the 65-plus crowd. In the TV spot, older Americans say they don't have “time for ...